DEVELOPMENT PHARMACEUTICAL SUBSTANCES

Brand Owner Address Description
NEURORESTORE AlzeCure Pharma AB HÄLSOVÄGEN 7 HUDDINGE 14157 Sweden Development of pharmaceutical substances for treatment and easement of Alzheimer's disease, only for human use; Scientific and technological services, namely, conducting early evaluations in the field of new pharmaceuticals, pharmaceutical drug development services, pharmaceutical product evaluation and pharmaceutical research and development; scientific research and design, namely, scientific research in the field of pharmaceuticals; Research in relation to pharmaceuticals; Research and development of vaccines and medicines; Conducting early stage evaluations in the field of new pharmaceuticals; Pharmaceutical drug development services; Drug discovery services; Technical data analysis services, namely, data analysis through data mining; Computer-supported technical analysis services, namely, chemical analysis, and data analysis through data mining;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. (Beauveria) sp. FO-6979 (FERM BP-6681), which belongs to the genus Beauveria and is capable of producing FO-6979-M0, -M1, -M2, -M3 and -M4 substances, is cultured in a medium to thereby accumulate the FO-6979-M0, -M1, -M2, -M3 and -M4 substances in the liquid culture medium. Then the FO-6979-M0, -M1, -M2, -M3 and -M4 substances are collected from the culture medium. The substances thus obtained are less toxic, specifically inhibit acyl-Coenzyme A: cholesterol acyltransferase, and inhibit the formation of oil droplets in macrophages. Owing to these characteristics, the above substances are useful in preventing and treating human diseases caused by cholesterol accumulation.